Furthermore, immunohistochemistry (IHC) of clinical samples from sorafenib treated HCC patients indicated better recurrence-free survival in HIF-2α negative and AR positive groups (Figures 4f and g). This evidence concerns the gene EPAS1 and hepatocellular carcinoma.